<?xml version="1.1" encoding="UTF-8" standalone="yes"?><xml><head><creation_date>D:20190801062500Z</creation_date><modification_date>D:20210519141800Z</modification_date><initial_authorization>False</initial_authorization><pdf_file>EU-1-13-846_h_dec_12.pdf</pdf_file></head><body><section><header>enen</header><p>european commission
 brussels, 17.6.2021c(2021)4569 (final)</p></section><section><header>commission implementing decisionof 17.6.2021
 amending the marketing authorisation granted by decision c(2013)4019(final) for 
 &quot;xtandi - enzalutamide&quot;, a medicinal product for human use following an assessment of 
 a periodic safety update report under article 28 of regulation (ec) no 726/2004</header><p>(text with eea relevance) (only the dutch text is authentic)</p></section><section><header>en</header><p>1</p></section><section><header>en</header></section><section><header>commission implementing decisionof 17.6.2021
 amending the marketing authorisation granted by decision c(2013)4019(final) for 
 &quot;xtandi - enzalutamide&quot;, a medicinal product for human use following an assessment of 
 a periodic safety update report under article 28 of regulation (ec) no 726/2004</header><p>(text with eea relevance)(only the dutch text is authentic)
 the european commission,
 having regard to the treaty on the functioning of the european union,
 having regard to regulation (ec) no 726/2004 of the european parliament and of the 
 council of 31 march 2004 laying down community procedures for the authorisation and 
 supervision of medicinal products for human and veterinary use and establishing a european 
 medicines agency
 1, and in particular article 10 and 28 thereof,having regard to the opinion of the european medicines agency, formulated on 22 april 
 2021 by the committee for medicinal products for human use on the periodic safety update 
 report for this medicinal product,
 whereas:
 (1)
 the placing on the market of the medicinal product &quot;xtandi - enzalutamide&quot; was 
 authorised by commission decision c(2013)4019(final) of 21 june 2013.
 (2)
 the marketing authorisation holder submitted a periodic safety update report for this 
 medicinal product. this report was assessed by the pharmacovigilance risk 
 assessment committee as to whether the marketing authorisation concerned should 
 be maintained, varied, suspended or withdrawn.
 (3)
 the scientific assessment performed by the committee for medicinal products for 
 human use, the conclusions of which are set out in annex iv to this decision, shows 
 that a decision should be taken amending the marketing authorisation for the 
 medicinal product concerned.
 (4)
 decision c(2013)4019(final) should therefore be amended accordingly. the union 
 register of medicinal products should also be updated.
 (5)
 for the sake of clarity and transparency, it is appropriate, following the amendment of 
 part or parts of the annexes, to provide for a consolidated version thereof. the 
 annexes to decision c(2013)4019(final) should therefore be replaced.
 (6)
 the measures provided for in this decision are in accordance with the opinion of the 
 standing committee on medicinal products for human use,
 1oj l 136, 30.4.2004, p. 1.</p></section><section><header>en</header><p>2</p></section><section><header>en</header><p>has adopted this decision:article 1decision c(2013)4019(final) is amended as follows:1) annex i is replaced by the text set out in annex i to this decision;
 2) annex ii is replaced by the text set out in annex ii to this decision;
 3) annex iii is replaced by the text set out in annex iii to this decision.
 article 2this decision is addressed to astellas pharma europe b.v., sylviusweg 62, 2333 be leiden, nederland.
 done at brussels, 17.6.2021
 for the commissionsandra gallina
 director-general</p></section></body></xml>